Hyperparathyroidism - Analysis And Market Forecasts To 2019
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the hyperparathyroidism therapeutics market. Reasons to buy- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hyperparathyroidism therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hyperparathyroidism therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Track drug sales in the global hyperparathyroidism therapeutics market from 2011–2019. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 1 Table of Contents1 Table of Contents 51.1 List of Tables 71.2 List of Figures 82 Introduction 92.1 Catalyst 92.2 Related Reports 92.3 Upcoming Related Reports 93 Disease Overview 103.1 Etiology and Pathophysiology 113.1.1 Etiology 113.1.2 Pathophysiology 123.1.3 Risk Factors 133.1.4 Prognosis 143.2 Epidemiology 143.2.1 Prevalence 143.2.2 Diagnosed Prevalence 153.3 Symptoms 163.4 Diagnosis and Referral 163.4.1 Diagnosis 163.4.2 Referral 173.5 Treatment Guidelines 183.6 Disease Management 193.6.1 Primary Hyperparathyroidism 193.6.2 Secondary Hyperparathyroidism 203.6.3 Tertiary Hyperparathyroidism 214 Competitive Assessment 224.1 Overview 224.2 Strategic Competitor Assessment 224.3 Product Profile - Major Brands 244.3.1 Sensipar (cinacalcet) 244.3.2 Zemplar (paricalcitol) 264.3.3 Hectorol (doxercalciferol) 284.3.4 Oxarol (maxacalcitol) 295 Opportunity and Unmet Need 315.1 Overview 315.2 Lower Adverse Effect on Serum Calcium and Phosphorus Level 325.3 New Treatment Options for Primary Hyperparathyroidism 325.4 Disease Awareness and Screening Programs in Primary Hyperparathyroidism 325.5 Convenient Dosing Regimen 325.6 Guidelines for Tertiary Hyperparathyroidism Management 325.7 Pricing 336 Pipeline Assessment 346.1 Overview 346.2 Strategic Pipeline Assessment 346.3 Pipeline by Phases of Development 346.3.1 Phase III Pipeline 346.3.2 Phase II Pipeline 356.3.3 Phase I Pipeline 356.3.4 Preclinical Pipeline 356.3.5 Discovery Pipeline 356.4 Pipeline by Mechanism of Action 366.5 Technology Trends Analytic Framework 376.6 Hyperparathyroidism - Promising Drugs in Clinical Development 386.6.1 CTAP101 396.6.2 KAI-4169 IV 417 Clinical Trials Mapping 437.1 Clinical Trials by Country 437.2 Clinical Trials by Phase 437.3 Clinical Trials by Trial Status 447.4 Prominent Sponsors 448 Current and Future Players 468.1 Overview 468.2 Trends in Corporate Strategy 468.3 Company Profiles 478.3.1 Amgen Inc. 478.3.2 Abbott Laboratories 488.3.3 Cytochroma Inc. 498.3.4 KAI Pharmaceuticals Inc. 508.3.5 Other Companies in the Hyperparathyroidism Therapeutics Market 519 Licensing and Partnership Deals 529.1 Overview 529.2 Key Deals and Alliances in the Past 12 Months 5210 Market Outlook 5310.1 Seven Major Markets Overview 5310.2 Regional Analysis 5510.2.1 US 5510.2.2 France 5610.2.3 Germany 5710.2.4 Italy 5710.2.5 Spain 5810.2.6 UK 5810.2.7 Japan 5910.3 Key Events 5910.4 Drivers and Barriers 6010.4.1 Drivers for the Hyperparathyroidism Market 6010.4.2 Barriers for the Hyperparathyroidism Market 6111 Appendix 6211.1 Abbreviations 6211.2 Bibliography 6311.3 Methodology 6511.3.1 Coverage 6511.3.2 Secondary Research 6511.3.3 Forecasting Methodology 6611.3.4 Primary Research 6811.3.5 Expert Panel Validation 6911.4 Physicians and Specialists Included in this Study 6911.5 About the Authors 6911.5.1 Analysts 6911.5.2 Global Head of Healthcare Research and Consulting 7011.6 About GlobalData 7011.7 Contact Us 7011.8 Disclaimer 70 List of Tables Table 1: Types of Hyperparathyroidism 11Table 2: Etiology of Primary Hyperparathyroidism 11Table 3: Etiology of Secondary Hyperparathyroidism 12Table 4: Risk Factors for Hyperparathyroidism 13Table 5: Prevalence of Secondary Hyperparathyroidism in Chronic Kidney Disease 14Table 6: Total Prevalence of Hyperparathyroidism in the Major Markets, 2011-2019 15Table 7: Diagnosed Prevalence of Hyperparathyroidism in the Major Markets, 2011-2019 15Table 8: Symptoms of Hyperparathyroidism 16Table 9: Diagnosis of Hyperparathyroidism 17Table 10: Adoption of Treatment Guidelines by Physicians 18Table 11: Treatment Guidelines for Hyperparathyroidism 18Table 12: Surgery Criterion in Primary Hyperparathyroidism 19Table 13: Monitoring Primary Hyperparathyroidism in Nonsurgical Patients 20Table 14: Leading Treatments for Hyperparathyroidism, 2012 22Table 15: Product Profile - Sensipar 24Table 16: Adverse Incidents - Sensipar 25Table 17: Sensipar SWOT Analysis, 2012 26Table 18: Product Profile - Zemplar 26Table 19: Zemplar SWOT Analysis, 2012 27Table 20: Product Profile - Hectorol 28Table 21: Hectorol SWOT Analysis, 2012 29Table 22: Product Profile - Oxarol 29Table 23: Oxarol SWOT Analysis, 2012 30Table 24: Overall Unmet Needs - Current Level of Attainment 31Table 25: Hyperparathyroidism - Phase III Pipeline, 2012 34Table 26: Hyperparathyroidism - Phase II Pipeline, 2012 35Table 27: Hyperparathyroidism - Phase I Pipeline, 2012 35Table 28: Hyperparathyroidism - Preclinical Pipeline, 2012 35Table 29: Hyperparathyroidism - Discovery Pipeline, 2012 35Table 30: Comparison of Mechanisms of Actions in Development for Hyperparathyroidism, 2012 36Table 31: Hyperparathyroidism - Promising Drugs in Clinical Development 38Table 32: Product Profile - CTAP101 39Table 33: CTAP101 SWOT Analysis, 2012 40Table 34: Product Profile - KAI-4169 IV 41Table 35: KAI-4169 IV SWOT Analysis, 2012 42Table 36: Hyperparathyroidism Therapeutics, Clinical Trials by Phase, 2012 43Table 37: Hyperparathyroidism Therapeutics, Clinical Trials by Status, 2012 44Table 38: Hyperparathyroidism - Overall Sponsor Mix, 2012 44Table 39: Key Companies in the Hyperparathyroidism Market, 2012 46Table 40: Amgen's Hyperparathyroidism Therapy Portfolio Assessment, 2012 47Table 41: Amgen's Hyperparathyroidism Therapy Portfolio SWOT Analysis, 2012 47Table 42: Abbott's Hyperparathyroidism Therapy Portfolio Assessment, 2012 48Table 43: Abbott's Hyperparathyroidism Therapy Portfolio SWOT Analysis, 2012 48Table 44: Cytochroma's Hyperparathyroidism Therapy Portfolio Assessment, 2012 49Table 45: Cytochroma's Hyperparathyroidism Therapy Portfolio SWOT Analysis, 2012 49Table 46: KAI Pharmaceutical's Hyperparathyroidism Therapy Portfolio Assessment, 2012 50Table 47: KAI Pharmaceutical's Hyperparathyroidism Therapy Portfolio SWOT Analysis, 2012 50Table 48: Portfolio Assessment - Other Leading Players in Hyperparathyroidism Market, 2012 51Table 49: Strategic Deals and Alliances for Hyperparathyroidism, 2012 52Table 50: Sales Forecasts for Hyperparathyroidism in the Seven Major Markets, 2011-2019 54Table 51: Sales Forecasts for Hyperparathyroidism in the US, 2011-2019 56Table 52: Sales Forecasts for Hyperparathyroidism in France, 2011-2019 56Table 53: Sales Forecasts for Hyperparathyroidism in Germany, 2011-2019 57Table 54: Sales Forecasts for Hyperparathyroidism in Italy, 2011-2019 57Table 55: Sales Forecasts for Hyperparathyroidism in Spain, 2011-2019 58Table 56: Sales Forecasts for Hyperparathyroidism in the UK, 2011-2019 58Table 57: Sales Forecasts for Hyperparathyroidism in Japan, 2011-2019 59Table 58: Key Events Impacting Sales for Hyperparathyroidism, 2012 59Table 59: Hyperparathyroidism Market - Drivers and Barriers, 2012 60Table 60: Key Launch Dates 66Table 61: Key Patent Expiries 67 List of Figures Figure 1: Parathyroid Glands 10Figure 2: Pathophysiology of Secondary Hyperparathyroidism 13Figure 3: Referral and Management of Secondary Hyperparathyroidism in CKD Patients 17Figure 4: Strategic Competitor Assessment of Marketed Products in Hyperparathyroidism, 2012 23Figure 5: Opportunity and Clinical Unmet Need in Hyperparathyroidism, 2012 31Figure 6: Hyperparathyroidism Therapeutics Pipeline by Phase of Clinical Development, 2012 34Figure 7: Hyperparathyroidism - Pipeline by Mechanism of Action, 2012 36Figure 8: Technology Trends Analytic Framework for Hyperparathyroidism Pipeline, 2012 37Figure 9: Technology Trends Analytic Framework - Unmet Need Gap Analysis, 2012 38Figure 10: Hyperparathyroidism Therapeutics, Clinical Trials by Country, 2012 43Figure 11: Hyperparathyroidism - Leading Companies Participating in Clinical Trials, 2012 45Figure 12: Sales Forecasts for Hyperparathyroidism in the Seven Major Markets, 2011-2019 54Figure 13: Seven Major Market Sales for Hyperparathyroidism by Region, 2011-2019 55
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV